We are a clinical-stage biotherapeutics company focused on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. We are currently developing three product candidates under our INOpulse platform, a proprietary pulsatile nitric oxide device system. The first is for the treatment of pulmonary arterial hypertension (PAH) , which is currently in Phase 3 clinical testing. The other two product candidates are for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) which are both in Phase 2 development.
The INOpulse platform is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. Use of inhaled nitric oxide is approved by the U.S. Food and Drug Administration (FDA) and other regulatory authorities across the world to treat persistent pulmonary hypertension of the newborn. An investigational new drug application, or IND, for INOpulse for the treatment of patients with PAH, which is a form of pulmonary hypertension that is closely related to persistent pulmonary hypertension of the newborn was filed in 2010. A second IND for INOpulse for the treatment of patients with pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH-COPD was filed in 2012. A third IND for INOpulse for the treatment of patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, was filed in 2017. Bellerophon has exclusive worldwide rights to the ongoing INOpulse programs and related intellectual property.